Congress Wealth Management LLC DE Has $2.13 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Congress Wealth Management LLC DE grew its position in shares of Repligen Co. (NASDAQ:RGENFree Report) by 10.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,858 shares of the biotechnology company’s stock after purchasing an additional 1,113 shares during the quarter. Congress Wealth Management LLC DE’s holdings in Repligen were worth $2,132,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Commerce Bank boosted its stake in shares of Repligen by 4.5% during the fourth quarter. Commerce Bank now owns 1,683 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 72 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC raised its position in shares of Repligen by 34.2% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 805 shares of the biotechnology company’s stock worth $145,000 after acquiring an additional 205 shares during the last quarter. Journey Strategic Wealth LLC bought a new position in shares of Repligen during the fourth quarter worth about $213,000. Aigen Investment Management LP bought a new position in shares of Repligen during the fourth quarter worth about $278,000. Finally, Corient Private Wealth LLC raised its position in shares of Repligen by 28.0% during the fourth quarter. Corient Private Wealth LLC now owns 7,011 shares of the biotechnology company’s stock worth $1,261,000 after acquiring an additional 1,532 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. KeyCorp raised their price objective on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. lowered their price objective on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. Finally, Stifel Nicolaus raised their price objective on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Repligen has an average rating of “Moderate Buy” and an average price target of $197.75.

View Our Latest Research Report on RGEN

Repligen Trading Down 0.4 %

NASDAQ RGEN opened at $158.16 on Monday. The company has a market cap of $8.84 billion, a price-to-earnings ratio of 632.67, a P/E/G ratio of 5.28 and a beta of 1.03. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13. The business has a 50 day moving average price of $172.77 and a 200-day moving average price of $177.53. The company has a quick ratio of 5.24, a current ratio of 6.35 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGENGet Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.01). The firm had revenue of $151.31 million for the quarter, compared to the consensus estimate of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company’s revenue was down 17.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.64 EPS. As a group, equities analysts expect that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the completion of the sale, the chief executive officer now owns 163,177 shares in the company, valued at $27,456,162.02. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the transaction, the director now owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Anthony Hunt sold 20,072 shares of Repligen stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the transaction, the chief executive officer now directly owns 163,177 shares in the company, valued at approximately $27,456,162.02. The disclosure for this sale can be found here. Insiders sold a total of 41,296 shares of company stock worth $7,550,643 over the last quarter. 1.20% of the stock is currently owned by corporate insiders.

About Repligen

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Read More

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGENFree Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.